HIPK1: a New Druggable Kinase Target for Treating Pathological Cardiac Hypertrophy
J Cardiovasc Transl Res
.
2024 Feb;17(1):230-232.
doi: 10.1007/s12265-023-10405-6.
Epub 2023 Jun 16.
Authors
Michail Spanos
#
1
,
Priyanka Gokulnath
#
1
,
Emeli Chatterjee
1
,
Dimitrios Varrias
2
,
Lingfei Sun
1
,
Saumya Das
3
,
Guoping Li
4
Affiliations
1
Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
2
Albert Einstein College of Medicine/Jacobi Medical Center, The Bronx, NY, USA.
3
Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. SDAS@mgh.harvard.edu.
4
Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. GLI21@mgh.harvard.edu.
#
Contributed equally.
PMID:
37326697
DOI:
10.1007/s12265-023-10405-6
No abstract available
Publication types
Editorial
MeSH terms
Cardiomegaly / drug therapy
Humans
Myocytes, Cardiac
Protein Kinases*
Protein Serine-Threonine Kinases*
Substances
Protein Serine-Threonine Kinases
Protein Kinases
HIPK1 protein, human
Grants and funding
1UG3 TR002878/TR/NCATS NIH HHS/United States
R35HL150807/GF/NIH HHS/United States
1R01HL150401/GF/NIH HHS/United States
1UG3 TR002878/TR/NCATS NIH HHS/United States